1: asymptomatic or severe SARS-CoV-2 positive patients2: Known history of porphyria, hemochromatosis or Viral hepatitis3: Patients with serious renal, hepatic, or cardiac disease etc.4: Patients who have lung disease that potentially become severe COVID-19 and who have poorly controlled hypertension and diabetes mellitus5: Pregnant or possibly pregnant women, lactating women, and women who desire to become pregnant during the study period 6:Patients participating in other clinical (human) trials7:Patients who have photosensitivity8:Patients who have alcoholism or severe mental disorder9:Demonstrate hypersensitivity to 5-aminolevulinic phosphoric acid or sodium ferrous citrate10:Patients who received COVID-19 approved drugs, excluding steroids, after the onset of COVID-19 symptoms11:Patients who received off-label use drugs available in Japan, excluding steroids, listed in the COVID-19 clinical guide after the onset of COVID-19 symptoms (including cases where they are used for purposes other than the treatment of COVID-19)12:Other patients judged to be inappropriate for the study by the attending physician

1: asymptomatic or severe SARS-CoV-2 positive patients2: Known history of porphyria, hemochromatosis or Viral hepatitis3: Patients with serious renal, hepatic, or cardiac disease etc.4: Patients who have lung disease that potentially become severe COVID-19 and who have poorly controlled hypertension and diabetes mellitus5: Pregnant or possibly pregnant women, lactating women, and women who desire to become pregnant during the study period 6:Patients participating in other clinical (human) trials7:Patients who have photosensitivity8:Patients who have alcoholism or severe mental disorder9:Demonstrate hypersensitivity to 5-aminolevulinic phosphoric acid or sodium ferrous citrate10:Patients who received COVID-19 approved drugs, excluding steroids, after the onset of COVID-19 symptoms11:Patients who received off-label use drugs available in Japan, excluding steroids, listed in the COVID-19 clinical guide after the onset of COVID-19 symptoms (including cases where they are used for purposes other than the treatment of COVID-19)12:Other patients judged to be inappropriate for the study by the attending physician

1: asymptomatic or severe SARS-CoV-2 positive patients2: Known history of porphyria, hemochromatosis or Viral hepatitis3: Patients with serious renal, hepatic, or cardiac disease etc.4: Patients who have lung disease that potentially become severe COVID-19 and who have poorly controlled hypertension and diabetes mellitus5: Pregnant or possibly pregnant women, lactating women, and women who desire to become pregnant during the study period 6:Patients participating in other clinical (human) trials7:Patients who have photosensitivity8:Patients who have alcoholism or severe mental disorder9:Demonstrate hypersensitivity to 5-aminolevulinic phosphoric acid or sodium ferrous citrate10:Other patients judged to be inappropriate for the study by the attending physician

1: asymptomatic or severe SARS-CoV-2 positive patients2: Known history of porphyria, hemochromatosis or Viral hepatitis3: Patients with serious renal, hepatic, or cardiac disease etc.4: Patients who have lung disease that potentially become severe COVID-19 and who have poorly controlled hypertension and diabetes mellitus5: Pregnant or possibly pregnant women, lactating women, and women who desire to become pregnant during the study period 6:Patients participating in other clinical (human) trials7:Patients who have photosensitivity8:Patients who have alcoholism or severe mental disorder9:Demonstrate hypersensitivity to 5-aminolevulinic phosphoric acid or sodium ferrous citrate10:Other patients judged to be inappropriate for the study by the attending physician